Status:
TERMINATED
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Advanced Adult Primary Liver Cancer
Carcinoma of the Appendix
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-smal...
Detailed Description
OBJECTIVES: I. Determine the uptake of motexafin lutetium in tumors and normal tissue of patients with intra-abdominal malignancies or non-small cell lung cancer. II. Determine the ratio of tumor to...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed or suspected diagnosis of 1 of the following:
- Intra-abdominal malignancy of 1 of the following types:
- Sarcoma
- Ovarian cancer
- Gastrointestinal malignancies, including, but not limited to, appendiceal cancer, colon cancer, or gastric cancer
- Non-small cell lung cancer
- Planning to undergo surgical resection of disease
- Disease has the propensity to spread to the peritoneal cavity (intra-abdominal malignancy patients)
- Performance status - ECOG 0-2
- WBC ≥ 2,000/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Bilirubin \< 1.5 mg/dL
- Creatinine normal
- Creatinine clearance ≥ 60 mL/min
- Body weight ≤ 130 kg
- No G6PD deficiency
- No porphyria
- No history of peripheral neuropathy ≥ grade 3
- Able to tolerate anesthesia and major surgery
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 1 month after study participation
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00087191
Start Date
May 1 2004
Last Update
January 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104